Companies: 48,874 Total Market Cap: 132391982605079.18

Newron Pharmaceuticals S.p.A.

SWX-NWRN

Healthcare Biotechnology

Rank #20006

Market Cap 187.86 M

Volume 38,645

Price 9.42

Change (%) 0.13%

Country or region

Italy

Newron Pharmaceuticals S.p.A.'s latest marketcap:

187.86 M

As of 05/19/2025, Newron Pharmaceuticals S.p.A.'s market capitalization has reached $187.86 M. According to our data, Newron Pharmaceuticals S.p.A. is the 20006th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	187.86 M
Revenue (ttm)	57.73 M
Net Income (ttm)	17.80 M
Shares Out	19.96 M
EPS (ttm)	0.86
Forward PE	0.00
Ex-Dividend Date	n/a
Earnings Date	09/16/2025

Market Cap Chart

Data Updated: 05/19/2025

Newron Pharmaceuticals S.p.A.'s yearly market capitalization.

Newron Pharmaceuticals S.p.A. has seen its market value grow from ₣38.37 M to ₣156.89 M since 2020, representing a total increase of 308.92% and an annual compound growth rate (CAGR) of 37.87%.

Date	Market Cap	Change (%)
05/19/2025	₣156.89 M	-5.56%
12/30/2024	₣174.16 M	97.16%
12/29/2023	₣88.33 M	219.35%
12/30/2022	₣27.66 M	-4.32%
12/30/2021	₣28.91 M	-24.65%
12/30/2020	₣38.37 M

Company Profile

About Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in the development of innovative therapies for central nervous system (CNS) disorders and pain management. Headquartered in Bresso, Italy, the company operates in Italy and the United States.

Key Products

Xadago (safinamide): A treatment for Parkinson’s disease, available in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the UAE, Japan, and South Korea.

Product Pipeline

Evenamide: An add-on therapy for schizophrenia and treatment-resistant schizophrenia, currently in Phase III clinical trials.
Ralfinamide: A treatment for rare neuropathic pain indications.

Strategic Partnerships

Collaboration with Zambon for the commercialization of safinamide.
License agreement with Meiji Seika Pharma Co., Ltd. for the research, development, manufacturing, and marketing of safinamide.

Founded: 1999

Frequently Asked Questions

As of 05/19/2025, Newron Pharmaceuticals S.p.A. (including the parent company, if applicable) has an estimated market capitalization of $187.86 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Newron Pharmaceuticals S.p.A. global market capitalization ranking is approximately 20006 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	Italy
Founded	1999
IPO Date	n/a
Employees	22
CEO	Stefan Weber
Sector	Healthcare
Industry	Biotechnology
Address	Via Antonio Meucci 3 Bresso, 20091 Italy
Website	https://www.newron.com